Enanta Pharmaceuticals, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions. Enanta also generates value through its collaboration with AbbVie, including royalty interests tied to glecaprevir, a component of a hepatitis C treatment regimen marketed by AbbVie. The company’s work combines medicinal chemistry, drug discovery, and clinical development to advance oral therapies aimed at areas with significant unmet medical need. Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals plays a specialized role in the biotechnology market by supporting both partnered products and its own pipeline of investigational medicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jay R. Luly Ph.D.
- Employees
- 120
- Headquarters
- Watertown, MA, United States
- Website
- www.enanta.com